[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Head and Neck CancerPancreatic CancerCancer Pancreas

Interventions

DRUG

[Ga-68]MTP220 PET/CT Scan

Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.

Trial Locations (1)

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Qiubai Li

OTHER